Literature DB >> 21691878

Assessment of oncologic control obtained after open versus laparoscopic nephroureterectomy for upper urinary tract urothelial carcinomas (UUT-UCs): results from a large French multicenter collaborative study.

Mehdi Mokhtar Ariane1, Pierre Colin, Adil Ouzzane, Geraldine Pignot, Marie Audouin, Jean-Nicolas Cornu, Baptiste Albouy, Julien Guillotreau, Yann Neuzillet, Sébastien Crouzet, Sophie Hurel, Frederic Arroua, Pierre Bigot, Charles Marchand, Pierre Olivier Fais, Alexandre de la Taille, Fabien Saint, Emmanuel Ravier, Alexandre Matte, Laurent Guy, Franck Bruyère, Morgan Rouprêt.   

Abstract

BACKGROUND: The purpose of this study was to compare the postsurgical survival of UUT-UC patients treated with ONU and LNU.
METHODS: Using a multi-institutional, national, retrospective database, we identified patients with UUT-UC who underwent radical nephroureterectomy by open access (ONU) or by the minimally invasive alternative (LNU). Survival curves were estimated using Kaplan-Meier method. A multivariate Cox model was used to evaluate the association between surgical approach and disease recurrence.
RESULTS: Overall, 609 patients were included (ONU = 459 and LNU = 150). The median age was 69.8 years (range 61.9-76), and the male-to-female ratio was 2:1. Postoperative complications occurred in 80 patients, with no significant difference between ONU and LNU on the whole (P = 0.64). The median follow-up was 27 months. There was no difference between the 2 procedures in the 5-year CSS or 5-year RFS. Moreover, the 5-year CSS (P = 0.053) and 5-year RFS (P = 0.9) for cases with locally advanced disease (pT3/pT4) were similar between ONU and LNU. In the multivariate analysis, the surgical procedure used was not found to be associated with survival. The main limitation of the study is its retrospective design, which is the result of the rarity of the disease.
CONCLUSIONS: There is no evidence that oncological outcomes for LNU are inferior to those for open surgery, provided that the appropriate precautionary measures are taken.

Entities:  

Mesh:

Year:  2011        PMID: 21691878     DOI: 10.1245/s10434-011-1841-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  34 in total

1.  Comparison of post-operative intravesical recurrence and oncological outcomes after open versus laparoscopic nephroureterectomy for upper urinary tract urothelial carcinoma.

Authors:  Lujia Zou; Limin Zhang; Hu Zhang; Haowen Jiang; Qiang Ding
Journal:  World J Urol       Date:  2014-04       Impact factor: 4.226

2.  Risk stratification of metastatic recurrence in invasive upper urinary tract carcinoma after radical nephroureterectomy without lymphadenectomy.

Authors:  Pierre Colin; Tarek P Ghoneim; Laurent Nison; Thomas Seisen; Eric Lechevallier; Xavier Cathelineau; Adil Ouzzane; Marc Zerbib; Jean-Alexandre Long; Alain Ruffion; Sébastien Crouzet; Olivier Cussenot; Marie Audouin; Jacques Irani; Solène Gardic; Pascal Gres; François Audenet; Mathieu Roumiguié; Antoine Valeri; Morgan Rouprêt
Journal:  World J Urol       Date:  2013-06-29       Impact factor: 4.226

3.  Urothelial carcinomas of the upper urinary tract are now recognised as a true and distinct entity from bladder cancer and belong fully to the broad spectrum of onco-urologic neoplasms.

Authors:  Morgan Rouprêt; Pierre Colin
Journal:  World J Urol       Date:  2012-09-27       Impact factor: 4.226

Review 4.  Laparascopic nephrectomy: different techniques and approaches.

Authors:  Tania González León
Journal:  Curr Urol Rep       Date:  2015-02       Impact factor: 3.092

5.  Intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinomas: predictors and impact on subsequent oncological outcomes from a national multicenter study.

Authors:  Evanguelos Xylinas; Pierre Colin; François Audenet; Véronique Phe; Luc Cormier; Olivier Cussenot; Alain Houlgatte; Gilles Karsenty; Franck Bruyère; Thomas Polguer; Alain Ruffion; Antoine Valeri; François Rozet; Jean-Alexandre Long; Marc Zerbib; Morgan Rouprêt
Journal:  World J Urol       Date:  2012-09-30       Impact factor: 4.226

6.  Robot-assisted versus laparoscopic nephroureterectomy for upper-tract urothelial cancer: A population-based assessment of costs and perioperative outcomes.

Authors:  Vincent Trudeau; Giorgio Gandaglia; Jonas Shiffmann; Ioana Popa; Shahrokh F Shariat; Francesco Montorsi; Paul Perrotte; Quoc-Dien Trinh; Pierre I Karakiewicz; Maxine Sun
Journal:  Can Urol Assoc J       Date:  2014-09       Impact factor: 1.862

7.  Oncologic outcomes for open and laparoscopic radical nephroureterectomy in patients with upper tract urothelial carcinoma.

Authors:  Koichi Kido; Shingo Hatakeyama; Naoki Fujita; Hayato Yamamoto; Yuki Tobisawa; Tohru Yoneyama; Takahiro Yoneyama; Yasuhiro Hashimoto; Takuya Koie; Ikuya Iwabuchi; Masaru Ogasawara; Toshiaki Kawaguchi; Chikara Ohyama
Journal:  Int J Clin Oncol       Date:  2018-02-12       Impact factor: 3.402

Review 8.  Oncologic outcomes obtained after laparoscopic, robotic and/or single port nephroureterectomy for upper urinary tract tumours.

Authors:  Maria J Ribal; J Huguet; A Alcaraz
Journal:  World J Urol       Date:  2012-10-25       Impact factor: 4.226

9.  Laparoscopic radical nephroureterectomy is associated with worse survival outcomes than open radical nephroureterectomy in patients with locally advanced upper tract urothelial carcinoma.

Authors:  Hyung Suk Kim; Ja Hyeon Ku; Chang Wook Jeong; Cheol Kwak; Hyeon Hoe Kim
Journal:  World J Urol       Date:  2015-10-23       Impact factor: 4.226

10.  Regional differences in practice patterns and associated outcomes for upper tract urothelial carcinoma in Canada.

Authors:  Michael Metcalfe; Wassim Kassouf; Ricardo Rendon; David Bell; Jonathan Izawa; Joseph Chin; Anil Kapoor; Edward Matsumoto; Jean-Baptiste Lattouf; Fred Saad; Louis Lacombe; Yves Fradet; Adrian Fairey; Niels-Eric Jacobson; Darryl Drachenberg; Ilias Cagiannos; Alan So; Peter Black
Journal:  Can Urol Assoc J       Date:  2012-12       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.